Clinical studies in multiple myeloma by Lund, Johan
From Department of Medicine, Huddinge, Division of Hematology 
Karolinska Institutet, Stockholm, Sweden 
CLINICAL STUDIES IN MULTIPLE MYELOMA 
Johan Lund 
 
Stockholm 2016 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print AB 2016 
© Johan Lund, 2016 
ISBN 978-91-7676-435-0 
Clinical Studies in Multiple Myeloma 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Johan Lund 
Principal Supervisor: 
Assoc. Prof. Hareth Nahi 
Karolinska Institutet 
Department of Medicine, Huddinge 
Division of Hematology 
 
Co-supervisor(s): 
Assoc. Prof. Evren Alici 
Karolinska Institute 
Department of Medicine, Huddinge 
Division of Hematology 
 
Assoc. Prof. Henrik Green 
Linköping University 
Department of Medical and Health Sciences 
Division of Drug Research 
 
Assoc. Prof. Maciej Machazcka 
Karolinska Institute 
Department of Medicine, Huddinge 
Division of Hematology 
Opponent: 
Prof. Frits van Rhee 
University of Arkansnas for Medicial Sciences 
Myeloma Institute for Research and Therapy 
 
 
Examination Board: 
Dr. Caroline Heckman 
University of Helsinki 
Institute for Molecular Medicine Finland 
 
 
Prof. Jan Palmblad 
Karolinska Institute 
Department Medicine, Huddinge 
Division of Hematology 
 
Assoc. Prof Fredrik Celsing 
Karolinska Institute 
Department of Medicine, Solna 
Division of Hematology 
  
 
 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Adrian and Klara 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
Multiple Myeloma (MM) is an incurably disease of the bone marrow. It is characterized by the 
uncontrolled growth of clonal plasma cells (PCs) and leads to production of non-functional 
gammaglobulin. Clinical features include loss of normal bone marrow function, defect bone structure 
and kidney failure. 
The first historical cases were described as “mollities ossium” in the 1840s. Atypical urine samples 
were described already in the 1840s but the specific pattern on electrophoresis of serum from MM 
patients was described in 1939. 
PCs are highly specialized cells derived from B-lymphocytes. Every single PC produces a single class 
of antibody - one heavy chain (IGH) of IgG, IgA, IgD or IgE class and one light chain (IgL) κ or λ. 
Current evidence suggests MM evolves from a non-malignant state – MGUS, Monoclonal 
Gammopathy of Undetermined Significance. 
Assessment of chromosomal abnormalities is powerful in predicting outcome and there are also data 
suggesting that different treatment modalities are more efficient in treating MM with certain 
abnormalities. 
The first modern treatment attempts were performed in the 1940s with urethane. Combination therapy 
of melphalan and prednisone (MP) was invented in 1969 and remained standard therapy until early 
2000s when Thalidomide and Bortezomib was introduced. Stem cell transplant as treatment for 
younger patients were evolved in the 1980s and is still standard therapy. 
Paper I is based upon a retrospectively collected database of all 1837 MM patients diagnosed at 15 
Swedish between the years 2000 to 2011. From this material, we selected all patients treated with 
melphalan and prednisone (MP) or MP with added thalidomide (MPT) in 1st 2nd 3rd and 4th lines of 
treatment, a total number of 888. A meta-analysis of six previous clinical studies comparing MP to 
MPT in previously untreated MM could show a 6 months benefit to MPT. In our study median OS 
from beginning of 1st line of treatment was 2.2/4.2 years after MP/MPT respectively, and in 2nd, 3rd 
and 4th line of treatment 1.8/2.9, 1.4/1.6 and 1.1/1.9 years (P < 0.0001, 0.003, 0.74 and 0.235). The 
benefit of MPT over MP was bigger in our study compared to the randomized clinical studies. Minor 
differences in patient characteristics could partly explain the difference, though the difference still 
remained after adjusting for these markers. 
In paper II, we show, in a pan-Nordic collaborative study, with patients from Sweden, Norway and 
Denmark, the impact of chromosomal abnormality of gain 1q21. From a cohort of in total 930 
patients, 347 patients, with known 1q21 status, were studied and divided into 3 groups; gain 1q21, 
other chromosomal abnormalities (del (13q), del (17p), t(4;14) and/or t(14;16)) (OA) and no 
chromosomal abnormalities (NA). We observed the most dismal outcome from the gain 1q21 group 
and best outcome in NA with OA in between, treating with conventional cytostatic drugs. Adding 
Thal, Bor or Len to treatment could overcome poor prognosis in the NA group, but not for patients 
with gain 1q21. 
Paper III and IV were both based on a prospective clinical study on Lenalidomide (Len) naïve 
relapsed or refractory MM patients, starting at the second line of treatment, in two parts, studying Len 
in combination with Dexamethasone (Dex). The first part, an observational study on LenDex in 
standard dosing up to 9 cycles with 133 participating patients showed a good response rate (79% ≥PR) 
and a median time to progression (TTP) of 19 months. At response, PR or better, and two more 
consolidating cycles, patients were offered to enter a randomized phase II study, randomizing between 
continuous LenDex treatment and Len as single drug. There was a statistically insignificant trend to 
better progression free survival (PFS) in the LenDex group. No difference in overall survival (OS) 
could be shown. 
In the fourth study we looked upon whether different single nucleotide polymorphisms (SNPs) in the 
ATP-binding cassette sub-family B member ABCB1 gene, encoding P-glycoprotein (P-gp) could have 
clinically effect on response rate and survival in the same patient cohort. P-glycoprotein is a 
transmembrane transport protein that is responsible for the extrusion of several drugs over the cell 
membrane. It is localized, among others, in the intestinal mucosa and the kidney tubules and this 
protein could both affect uptake and excretion of several drugs. ABCB1 is known as a marker for 
resistance to different chemotherapeutic agents. In our study we could show no significant differs in 
response or survival data between groups with different SNPs in the ABCB1 gene in the whole 
population, but in the low risk group according to cytogenetics, there was a significant difference in 
time to progression from difference in SNP in 1199G>A genotype, favoring patients with G/A over 
G/G genotype. 
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1 BACKGROUND 
 
 
Introduction 
Myeloma is currently an incurable malignant disease. It stands for about 2% of 
all cancer deaths and about 20% of all hematological malignancies(1). It is 
stated as a systemic malignant disease of the blood and the World Health 
Organization defines it as a lymphoproliferative B-cell disease. It is 
characterized as an uncontrolled proliferation of plasma cells (PC) in the bone 
marrow leading to extensive production of non-functional intact 
gammaglobulin or parts thereof. It can affect bone structure via enhancing 
osteoclasts, impair kidney function via hypercalcemia or have direct effect on 
tubulus of the defect gammaglobulins and cause loss of bone marrow function. 
 
History 
The first two recorded cases of what might have been multiple myeloma, but at 
that time was named “mollities ossium” were described by Samuel Solly in 
1844 of two women, one of them Sarah Newbury, with severe and multiple 
fractures combined with fatigue. At the autopsies, the bones were particularly 
weak and under the microscope ”…the osseous structure of the bone was nearly 
absorbed, a mere shell being left. The interior was filled with a dark grumous 
matter, varying in colour from that of dark blood to a reddish light liver colour.”  
 2 
(2).   
              
 
Figure 1. Sarah Newbury, the first known MM patient 
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In 1845, a 38-year-old London grocer, Thomas Alexander McBean, referred to 
Dr William Macintyre of Harley Street after having had severe chest pain and 
had noticed that his “body linen was stiffed by his urine”. Dr Macintyre noticed 
severe body pain and peripheral oedema and precipitated a urine sample 
searching for albumin, finding somewhat odd results and sent a sample to Dr 
Henry Bence Jones, chemical pathologist at St George’s Hospital, London. At 
the same time, the patient’s GP, Dr Thomas Watson had sent another urine 
sample to Dr Bence Jones with the same question. Dr Bence Jones analysed the 
urine and determined the sediment to be different from albumin, mistaking it 
for being an oxide of albumin(3). Mr McBean passed away 1846 and during the 
autopsy, they noticed “…that all the ribs throughout their whole length were 
soft and brittle, so that they could be easily cut by the knife…”, and “…their 
interior was charged with a soft gelatiniform substance of blood-red colour 
and unctuous feel…”(4). Histologically, they described large numbers of 
nucleated cells in the affected bones(3), but the term “plasma cells” were first 
used thirty years later by Waldeyer (what he probably described were Mast 
Cells(5), but he invented the actual term)(6). The term “Bence Jones protein” 
was never used by H Bence Jones himself, it was first used by a Dr Fleicher in 
Erlangen 1880(3).  Bayne-Jones and Wilson first described two different 
types of Bence Jones proteins in 1922(6), and 1956 Leonard Korngold and his 
assistant Rose Lipari could identify two different types of Bence Jones 
proteins and could also show that they shared some of the antigenic 
determinants of homologous MM-globulin from serum(5). Later on the two 
different chains κ and λ were named in their honor(3). The specific pattern of 
MM in serum electrophoresis was shown in 1939(7). Prof Waldenström 
developed the concept of clonality in 1960(8) and in 1962 Edelman and Gally 
could show that Bence Jones protein and light chains of the serum shared the 
same characteristics(9). 
 
Pathogenesis 
 
Plasma Cell Development 
 
Normal PCs are highly specialized cells derived from B-lymphocytes. Every 
PC producing a single type of antibody containing one class of immunoglobin 
heavy chain (IgG, IgA, IgE or IgD) and one class of light chain (κ or λ). The 
early B-cells develop from hematopoetic stem cells in the bone marrow, 
where they rearrange their heavy chain (IgH) gene segments and become 
precursor B-cells which express IgM and leave the bone marrow. They 
migrate to the spleen and become either marginal zone B-cells or follicular B-
cells. The marginal zone B-cells are short lived and can react quickly on 
antigen stimulation, producing IgM and then die from apoptosis within one 
week.  Follicular B-cells can also undergo the same quick maturation and 
become IgM-producing PCs, but can also undergo maturation in the germinal 
centers, where they would be co-stimulated with dendritic cells and T-cells 
and subsequently undergo somatic mutations of the immunoglobin genes. 
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Memory B-cells arise from germinal centers. B-cells with mutated 
immunoglobin genes, but still expressing BCR and not producing antibodies 
and mature and long-lived PCs. The memory B-cell circulates and supplies a 
rapid and strong response when stimulated with the same antigen that 
activated its parent B-cell. The PC circulates and eventually goes back to the 
bone marrow, producing high levels of antibodies, but do not proliferate. PCs, 
per definition, do not express BCR and can therefore not take up antigen and 
they lack MHCII and can no more act as antigen presenting cells. They live 
for some weeks, up to several months, but there is evidence that some of them 
might migrate to the bone marrow and live there for several years.(10) 
 
During the development of early B-cells to PCs, they will rearrange their 
immunoglobin genes, both the heavy chain (IgH) genes and thereafter the 
genes coding for the light chains. The very large IgH gene is located on 
chromosome 14 and consists of 4 major domains. The variability domain 
(VH) consists of more than 100 DNA segments, the diversity domain (DH) of 
27 DNA segments, the joining domain (JH) of 6 segments and constant 
domain of 6. The early rearrangement process is driven by specific enzymes, 
recombination activating genes (RAG) 1 and 2 of chromosome 11p, that first 
combine a fragment of the DH and a fragment of JH and then join this DH-JH 
with a VH fragment. If this combination is in frame the cell will go on 
activating the light κ chain gene (IgLκ) on chromosome 2 and the cell will 
become a mature IgM-κ producing cell. When the cell is unable to produce 
light κ-chains, it will in turn activate the light λ gene (IgLλ) on chromosome 
20 and the cell will become an IgM-λ producing B-cell. This explains why 
there are double as much κ producing cells as λ producing ones. This process 
occurs stochastically and antigen independent. 
 
The cell then leaves the BM and finds its way into the secondary lymphoid 
organs. The second type of gene rearrangement occurs in the presence of 
antigen presenting cells and T-cells. New stochastic mutations will occur in 
the IgH DH-JH-VH complex and only cells producing antibodies more 
specific for the presented antigens will survive; the others will go into 
apoptosis. The last stage will be the class switch recombination, also in the 
secondary lymphoid organs, turning the B-cells into specific IgG, IgA or IgE-
producing B-cells. These cells will finally mature to PCs or memory B-
cells.(11) 
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Plasma Cells Development into Multiple Myeloma 
MM develops from premalignant clonal PCs that have gone through the 
maturation process in germinal centers(1), but as PCs lack proliferative 
capacity, MM may evolve from memory B-cells(12). These cells would be the 
myeloma initiating cells and initiate disease but also serve as a reservoir of 
cells to induce disease relapse. 
MM evolves in probably all cases from a non-malignant pre-stadium, MGUS -
“monoclonal gammopathy of undetermined significance” (13). 3 % of all 
people older than 50 years have MGUS(14). The Annual follow up of MGUS 
patients have shown a MM development rate of 1 %(13). A subset of these 
patients is first diagnosed with smoldering myeloma – a condition that shares 
the diagnostic criteria with MM, but lack symptoms. 
 
Chromosomal Abnormalities 
Based on chromosomal analysis, the chromosome number pattern is a powerful 
prognostic factor in patients with MM. In general, loss of genetic material (such 
as hypodiploidy) in almost all malignancies is a marker of poor prognosis, 
whereas gains (such as hyperdiploidy) are usually associated with better 
outcome. Most probably because hypodiploidy cause loss of functions such as 
tumor suppressor functions, while hyperdiploidy causes gain of function that 
not always leads to interference with the cell cycle. 
Hypodiploidy 
The incidence of hypodiploidy is about 10% (15, 16). The importance of 
hypodiploidy for overall survival in MM is unclear. An adverse effect of 
hypodiploidy in general may be due to monosomy of specific chromosomes, 
where the general hypodiploidy might be a confounding factor. However 
correlations with adverse OS have been found in multivariate analysis 
independent of other aberrations (17, 18).  
Hyperdiploidy 
Chromosomal abnormalities are present in nearly all cases of MM. There are 
two described different pathways for abnormalities that drive the cells into 
MM. The first is represented by hyperdiploidy and involves the chromosomes 
3, 5, 7, 9, 11, 15, 19 and 21and is seen in a bit more than 30% of patients(19). 
How the hyperdiploidy drives the MM evolution is today not fully understood. 
The other one is based upon IgH translocation, especially located to 
chromosomal locus 14q32(20).  
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Immunoglobin heavy chain (IgH) aberrations 
Any gene that is translocated to be fused to the enhancer of the IGH gene in a 
PC will be highly expressed (1). Translocations to the IgH locus occurs in about 
50% of MGUS, 60-65% of intramedullary MM and in 70-80% in 
extramedullary MM(21), indicating a gain of more mutations throughout the 
development of the disease.  
t(11;14)(q13;q32) 
The most frequent translocation including 14q32 is t(11;14)(q13;q32) occurring 
in approximately 30% of MM patients leading to dysregulating of CCND1, and 
consecutive overexpression of cyclin D1(22). MM patients with t(11;14) have a 
higher tendency of a non-secreting disease, morphology of a 
“lymphoplasmacytic” type and occur in high frequency in IgM MM(23, 24). 
t(4;14), t(14;16) and t(14;20) 
The second most common is t(4;14)(p16;q32), occurring in about 12-15% of 
MM patients leading to up-regulating of MMSET due to translocating this gene 
to the IgH-locus at 14q32 and, in turn, up-regulating of the fibroblast growth 
factor receptor 3 gene FGFR3(25). FGFR3 is a receptor tyrosine kinase(26) and 
is thus a possible target for therapy with receptor tyrosine kinase inhibitors (27). 
t(14;16)(q32;q23) also causes over-expression of  c-maf (musculoaponeurotic 
fibrosarcoma) (28) which is a proto-oncogene(29). Another maf gene is the 
mafB which strongly correlates to t(14;20)(q32;q12), a translocation occurring 
in about 1-2% of all MM patients and strongly associated with poor prognosis 
(30), (31), (32). While patients with t(14;16) and t(14;20) have an equally 
aggressive disease as those with t(4;14) (33); due to the lower frequency of  
t(14;16),  its significance is conclusive only in larger studies (33). So far, 
t(4;14) and t(14;16) translocations are considered to be specific for MM, no 
other known malignancy carries these aberrations. 
Less frequent translocations are t(6;14)(6p21,q32), t(8;14)(q24;q32) and 
t(14;20)(q32;q11). 
 
Structural aberrations  
Chromosome 1 
Structural aberrations of chromosome 1 are the most frequent ones in MM and 
are identified in 40-48% of all cases (19, 34). The most common aberration is 
gain of 1q21 which is seen in 40% of all newly diagnosed MM cases, and in 
about 70% of relapses (35) while it is quite rare in MGUS. Since gains of 1q are 
frequently seen at late stages of the disease, the locus is considered to play a 
pathogenic role in disease progression and gains are therefore associated with 
poor prognosis (35-37). 
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del (8p21)  
Previous studies have linked molecular dysregulations originating from changes 
in the 8p21 region to various malignancies including leukemic mantle cell 
lymphoma (38) and B-cell lymphoma (39), and the loss of this region has been 
shown to have a negative effect on survival in head and neck cancers. Our 
group has previously reported that del(8p21), is an independent poor prognosis 
factor in MM and both progression free survival (PFS) and OS are adversely 
affected (40). 
del (8q24)  
8q24 encodes the c-myc gene. Gene expression profiling studies have pointed 
out the MYC pathway as a key player in the evolution of normal PCs  to MM 
(41). The most well-known is t(8;14)(q24;q32) which is associated with 
Burkitt’s lymphoma and NHL, and also described in MM. 
Chromosome 13 
Deletion of 13q or the whole chromosome 13, identified by FISH in less than 
50% of the patients, has for many years been considered to be an adverse 
prognostic factor (42). However, in the earlier studies the association with poor 
prognosis was based on conventional cytogenetics and in almost all new studies 
using FISH and multivariate analysis including other chromosomal 
abnormalities the loss of 13q is not an independent prognostic factor (43-47). 
del (17p) (p53) 
This abnormality is a strong predictor of extremely low OS and the lowest rate 
of achieving CR in comparison to other or no abnormalities (48, 49). Deletion 
of 17p is probably one of the most predictive molecular markers for resistance 
to therapy and short OS in MM identified so far (36, 48). Neither high dose 
therapy nor allogeneic transplantation seems to overcome the dismal prognosis 
for patients with TP53 deletions/mutations (45, 48). 
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Genomic Aberration Incidence (%) 
del(13q) ∼50 
14q32 Translocations ∼50–60 
Hyperdiploidy ∼50 
t(4;14) ∼15 
t(11;14) ∼15 
t(14;16) ∼5 
t(14;20) ∼1 
del(17p) ∼10 
gain(1q21) ∼30–43 
del(1p21) ∼20 
Table 1. Incidence of Chromosomal Abnormalities in MM 
Data from van de Donk et al (50) 
 
Other dysregulations 
A number of gene dysregulations, such as activation of N- and K-Ras(51), or 
the tumor suppressors TP53, phosphatase and tensin homolog gene (PTEN), 
Cyclin-dependent kinase inhibitor 2A (CDKN2A) and Cyclin-dependent kinase 
4 inhibitor C (CDKN2C) are known to have prognostic impact(1). The latter 
are believed to be secondary events in the MM-cell evolution. The IgH 
translocations are often seen in all of the PCs of a patient, however in these 
dysregulations only in certain subclones(11). 
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Clinical Features of Multiple Myeloma 
 
Epidemiology 
 
MGUS, the premalignant stage that may precede MM is found in about 1% of 
the population older than 25 years and in 3-4% in people older than 50(26, 
52). About 1% of the patients with MGUS progress to MM every year(13). 
The progress into symptomatic MM is much higher of patients with 
smoldering MM, about 5% at a yearly rate(52). 
The incidence in US is 5.6 per 100 000 person-years with a higher incidence 
in males than women (7.1 vs. 4.5/100 000 person years)(53). The Swedish 
incidence is 6.6/100 000. Due to better treatment modalities and longer 
survival the prevalence of the disease has risen. In 1980s’ Sweden, a bit more 
than 1 000 patients lived with the disease and in 2012 the number had more 
than tripled (3 107). Some of the rise in prevalence can be due to shift in 
diagnostic criteria and the population number has also increased from 8 
million inhabitants to nearly 10 million.(54) 
 
Diagnosis 
 
MM diagnosis is based on the presence of at least 10% clonal PCs  in the 
bone marrow combined with at least one of four CRAB criteria (increased 
serum calcium level, renal dysfunction, anemia, and destructive bone lesions). 
(i.e. calcium level >2.75mmol/L, creatinine clearance <40 ml/minute, 
hemoglobin value of >20g/L below lowest limit of normal or below 100 g/L 
and one or more bone lesion on skeletal X-ray or CT-scan). In the last edition 
of International Myeloma Working Group’s diagnostic criteria there has been 
added three more Myeloma Defining Events (MDEs) of the asymptomatic 
patient that also calls for treatment; 60% or more clonal PCs on bone marrow 
examination, serum free light chain ratio of 100 or greater, provided the 
involved chain level is at least 100 g/L, more than one lesion on Magnet 
Resonance Imaging (MRI), greater than 5mm in diameter. 
MGUS is diagnosed from less than 10% clonal PCs  of the bone marrow and 
an M-component in plasma less than 30 g/L and no CRAB-criterias up filled. 
Smoldering myeloma is diagnosed from 10-60% PCs in bone marrow or an 
M-component of >30 g/L.(55) 
 
Risk Stratification 
 
The standard MM risk estimation of MM has been based upon two risk 
scores. The Durie Salmon system(56) is based upon hemoglobin level, 
calcium level, number of lytic bone lesions and level of M-component in a 
way of estimating tumor mass and kinetics and transform it into prognosis. 
The ISS score was evaluated from univariate and multivariate analyses of 
 10 
several potential predictors of survival in MM and form these markers a 
combination of β2-microglobulin and albumin provided “…the simplest, most 
powerful and reproducible three-stage classification.”(57). 
 
However, these risk scores take no account of chromosomal abnormalities, 
differential gene expressions nor other factors such as age and performance 
status. Numerous further studies have validated the influence of those 
biological factors’ influences on MM-risk(58). 
t(4;14) is considered as associated with a shorter PFS and OS(59). t(14;16) 
with up-regulated cyclin D1, a driving mutation in mantle cell lymphoma, was 
supposed to be a negative prognostic marker in MM, but has proven to have 
no impact on prognosis and is now considered as a standard risk marker(58-
60). 
del (17p) is repetitively shown to be a negative prognostic marker(43, 61, 62). 
TP53 is located on the short arm of chromosome 17 and is probably the cause 
of the negative impact on survival of this deletion. TP53 as a tumor 
suppressor gene and its role in survival of tumors cells after treatment is well 
described(63). 
del (13q) can be observed in half of the patients with MM. Its role as a 
prognostic marker has been controversial. It has initially been proposed as a 
negative prognostic marker, but further studies have shown this to be mainly 
related to its frequent association to t(4;14) or del 17p(43, 62, 64). It is no 
longer considered as an independent prognostic marker in the absence of 
t(4;14) or del (17p) when evaluated by FISH(23, 24, 43, 62). When it is 
detected by conventional cytogenetics it comes out as a negative prognostic 
marker(65), probably due to that cytogenetics is a less sensitive method than 
FISH in detecting del (17p) and t(4;14) and del (13q) therefore seem to be a 
surrogate marker for those. 
Also dysregulation of genes on chromosome 1 affects outcome. Gain 1q21 is 
linked to a poor prognosis(66-68), probably by dysregulation of CKS1B, a 
cell cycle regulator. It is also shown the more copies of 1q21, the worse 
outcome(69). Del 1p is also a negative prognostic marker, especially when 
linked to gain 1q21(70). 
Del 8p21 has also by two groups been linked to a poor prognosis, but the 
results must be confirmed by other studies(40, 71). 
 
 
Several attempts have been made to show the possibility of influencing the 
impact of prognostic markers by choosing the right treatment. It is shown that 
addition of Bortezomib (Bor) can partly overcome the negative impact of 
t(4;14)(72) and that use of Bor both in induction and thereafter as 
maintenance therapy can partly overcome the negative impact of del 
(17p)(69). Our own retrospective study could show that use of Thal, Bor or 
Len could overcome the negative prognosis of t(4;14), t(14;16) del13q and 
del17p compared to conventional cytostatic drugs, but not the negative impact 
of gain1q21(67).  
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Treatment Development 
 
MM responds to both classical cytotoxic, immunomodulatory and other 
targeted drugs, as well as to autologous- and allogeneic stem cell 
transplantation(73) 
The reigning assumption is that the correct combination of available treatment 
modalities will improve survival and even cure a fraction of the patients. 
Assessing prognostic parameters, in particular chromosome aberrations, up-and 
down-regulation of certain gene products, evaluation of different drug effect on 
different patient populations and analyses of other cell population of the patient 
e.g. natural killer (NK)–cell function or osteoclast activity will be helpful in 
selecting the best treatment regimen for the patients. 
Still, MM is considered to be an incurable disease, due to the persistence of 
residual tumor cells(74, 75), but there are several new drugs and new 
combinations oncoming. 
Early treatment attempts of MM were rhubarb pills and infusion of orange peel 
which was given to Sarah Newbury in 1844(2). Mr. McBean was given steel 
and quinine but was also subjected to phlebotomy and application of leeches(4). 
The first modern attempt to treat MM was in 1947 when the nephrologist 
Alwall in Lund (Sweden) started treatment with urethane(76, 77). This became 
the standard therapy for 15 years until Holland et al in 1966 randomized 83 
patients to receive either urethane or placebo, showing no survival difference 
between the groups(6, 78). 
In 1958, Blokhin et al reported the first data on treating MM with 
melphalan(79), followed by studies by Bergsagel and Hoogstraten in 1962, and 
1967(80, 81). In 1962, Mass could show effect in lowering the serum globulin 
and rise in hematocrit on giving prednisone to MM patients, but could show no 
survival benefits compared to placebo(82). 
The first efficient therapy against MM was the combination of melphalan and 
prednisone (MP), described by Alexanian and colleagues in 1969(83). This was 
standard therapy for decades. 
The first attempts to perform bone marrow transplant were reported by Thomas 
et al in a series of six case studies publicized in 1957(84). All patients died from 
their disease, but no acute reactions from the transplanted bone marrow could 
be shown. It was not until the 80s, that studies on bone marrow transplant on 
MM with successful results were published. The first results from syngenic 
(twins) transplant were published in 1982 and 1986(85, 86) and in 1987 
Garhton et al published a series of 14 patients with MM, transplanted with 
HLA-identical graft from siblings. 10 patients survived 6-34 months after 
transplantation with a median OS of 12 months(87). Research continued on 
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allogeneic transplant of MM, but in 1997 Bensinger et al published data from 
all patient registers of allogeneic stem cell transplant, including European Bone 
Marrow Transplant (EBMT) registry and the International Bone Marrow 
Transplant Registry (IBMTR)(88). They reported that 28%, of the patients lived 
7 years after allogeneic transplant and possibly were cured, but a very high rate 
of transplant-related mortality, 41%, made the median OS short compared to 
that of autologous stem cell transplant, 18 vs. 43 months and the 
recommendation was to spare allogeneic transplant for selected patients. 
Autologous stem cell transplant of MM with melphalan 140mg/m2 was first 
reported in 1983 by Mcelwain and Powles(89). Out of 9 patients reported, one 
previously untreated with plasma cell leukemia, 4 previously untreated with 
MM and 4 previously treated with MM all responded to treatment and 3 out of 
the 5 untreated responded with CR. In 1987 Barlogie et al(90) reported on 7 
patients that had relapsed or were refractory to both MP and VAD. They were 
given melphalan 140 mg/m2 and TBI of 8.5 Gy followed by the infusion of 
autologous stem cells. All patients responded to treatment, two died after 2.5 
and 3 months from pneumonia and osteomyelitis, but the rest were treatment 
free 2, 6, 11, 15 and 21 months after treatment. During the upcoming 10 years, 
several other studies showed survival benefit for high dose treatment with 
melphalan followed by the administration of peripherally harvested blood stem 
cells(91). 
For the elderly, non-transplant eligible patients, however, there still were no 
better alternative treatment modalities than the combination of MP. An 
overview of 27 randomized trials of melphalan and prednisone versus different 
newer combination chemotherapies could show no benefit for the latter(92). 
 
 Introduction of IMiDs as MM drug 
30 years after the introduction of MP, Barlogie and his colleagues could show 
that, in a group of 84 patients, refractory to standard treatment, 32% responded 
to treatment with thalidomide as a single agent(93).  
Thalidomide was initially approved as a sedative and a treatment modality of 
pregnancy related morning sickness and nausea. Due to the company’s explicit 
claim of safety it was approved as an over-the-counter drug in West Germany 
1957 and soon after it was approved in more than 40 countries. 
It was the work of the chief scientist of Chemie Grünenthal, a small West 
German pharmaceutical company. They were searching for new antibiotics and 
produced α –phthalimidoglutarimide, which they called thalidomide. They had 
no idea about this new molecule’s pharmacological properties and started 
searching for certain pharmacological activity. The drug showed no antibiotic 
activity, and in fact, no other pharmacological action at all in rats and mice, and 
this made up the thought that the drug was completely harmless. Encouraged of 
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its presumed non-toxic properties the company thought, “a nonlethal sedative 
would have enormous market potential.” The problem with sedatives at this 
time, mostly barbiturates, was that they were easy to commit suicide with, but 
this drug was later advertised as “a completely safe solution to the mounting 
toll of barbiturate deaths.” 
Reports from Australia and Germany could in November 1961 link the use of 
thalidomide to the rise of infants born with severe birth defects, which led to a 
publication in a newspaper in December the same year and thereby a rapid 
withdrawal of the drug from all markets. About 8 000-12 000 children were 
born with birth defects and out of them 5 000 survived beyond childhood. 
Some years later, in 1965, Jacob Sheskin, a physician at a French hospital 
tested thalidomide in the treatment of a terminally ill patient with erythema 
nodosum leprosum (ENL) - a complication of leprosy. Sheskin found a bottle 
of 20 tablets with thalidomide, though he knew the drug was banned; he also 
remembered that the drug was used as a sleeping pill. The patient was dying 
and in extreme pain so Sheskin felt he had nothing to lose and gave the patient 
two pills. The patient slept for 20 hours, woke up and could leave the bed 
without assistance. Several trials on thalidomide treatment on ENL were made 
and one randomized study showed up with favorable results. During the coming 
years use of the drug was tested for several immune defect disorders.(94) 
Several studies have tried to determine the mechanisms of thalidomide action. 
In 1991, it was shown that thalidomide inhibits tumor necrosis factor alpha 
(TNF-α) in an in vitro study(95). Two years later the same group demonstrated 
that thalidomide could decrease levels of TNF-α in patients with ENL(96). 
Later, in vitro studies could show thalidomide’s effects on T-cells, shifting from 
a Th1 to a Th2 phenotype by lowering of IL2 and IFN-gamma(97). 1994 
D’Amato et al could show anti-angiogenic effect due to down-regulation of 
basic fibroblast growth factor(98) and inhibition of angiogenesis could later be 
shown as an effect of down-regulation of VEGF due to thalidomide, in a study 
of corneal vascularization on rabbits(99). 
During the 90s, one of the main theories on searching for a cure against cancer 
was based upon finding ways to inhibit the tumors’ ability to induce 
angiogenesis: thus making up for Barlogies study, where the hypothesis was 
based upon the anti-angiogenic properties of Thal and the prominent bone 
marrow vascularization seen in MM. 
6 randomized clinical studies were later on performed to compare the effect of 
adding thalidomide to MP (MPT) compared to that of MP(100-105), and a 
meta-analysis of those studies could show an overall survival benefit of 6 
months for MPT(106), thus consolidating thalidomide’s status as an efficient 
MM drug. 
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Second Generation IMiDs 
Later on, attempts were made to find new IMiDs in search for drugs with less 
side effects and higher potency. Lenalidomide (Len) was approved in 2006 and 
Pomalidomide in 2012 and today IMiDs are the backbone for various treatment 
regimens of MM.  
Len was first presented as a potentially more potent analogue to thalidomide, 
but lacking side effects as somnolence, obstipation and neuropathy(107). Two 
randomized clinical studies presented in 2007 could show its potency in treating 
relapsed MM(108, 109) and upon the results from these two studies both the 
US Federal Drug Agency (FDA) and the European Medicines Agency (EMA) 
2006 granted approval for the use of Len in combination with dexamethasone 
for the use in second line of MM-therapy(110). Results from the FIRST 
trial(111), where continuous use of LenDex compared with LenDex for 72 
weeks and MPT for 72 weeks, could show better PFS for continuous use of 
LenDex was the basis for the approval for use of Len in first line treatment in 
patients ineligible for autologous stem cell transplantation both from FDA and 
EMA. 
Pomalidomide was approved upon the MM-003-study comparing 
pomalidomide in combination with low dose Dex to high dose Dex as single 
drug in patients that had received at least two previous lines of therapy 
including Len and Bor. PFS for combination of pomalidomide and 
dexamethasone in this heavily pretreated group was 4.0 months compared to 
1.9 months for high dose dexamethasone(112). 
 
IMiDs and their Mechanism of Action 
Though used as standard treatment for MM, the primary target for IMiDs anti-
MM effect was unknown until 2010 when dr. Ito in a study of the teratogenic 
effects of Thalidomide could show that Thalidomide binds to a protein called 
cereblon(113). A study from 2014 could show that lack of cereblon expression 
in bone marrow samples of MM-patients correlated with inferior survival in 
patients treated with a Len- or Thal-based treatment regimen, but not with a 
regimen based upon Bor(114), thus making it clear that cereblon is essential for 
anti-MM activity. 
Cereblon forms an ubiquitin ligase complex with DDB1, CUL4A and ROC1. 
When activated by IMiDs it ubiquitinates the two transcription factors IKZF1 
and IKZF3, also named Ikaros and Aiolos, which in turn will be degraded in the 
proteasome(115). The absence of those two factors will in turn cause down-
regulation of the two transcription factors IRF4 and MYC. These two are 
essential for the survival of the MM cell(116), and their absence will lead to the 
death of the MM cell. Interestingly IRF4 stimulates the production of MYC, 
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which in turn stimulates the production of IRF4, making an auto regulatory 
circuit in MM-cells(116). 
IMiDs have numerous effects at the immune system as mentioned above. It has 
a large anti-inflammatory property as decreasing TNF-α, however TNF-α levels 
of the bone marrow of MM-patients are low. IMiDs also lower the levels of the 
pro-inflammatory factors IL1, IL6, IL12 and Cox 2 and raises levels of the anti-
inflammatory factor IL10. Whether it is the IKZF1/IKZF3-pathway that leads 
to those effects of IMiDs or if there are more targets is unknown. It is shown, 
that IKZF3 binds to the IL2 gene promoter and represses the IL2 production in 
CD4+ T-cells, and that addition of Len induces IL2 production. The same study 
could also show abrogated Len effect on IL2 in cells with their Cereblon gene 
knocked down(115). One theory of MM development is set upon its ability to 
avoid immune response upon down-regulation of NK-cells. NK-cells have the 
capacity of directly target tumor cells and kill them, and are therefore 
considered to be a keystone in the organism’s defense against 
malignancies(117). NK cells are directly up-regulated by IL2(118), and so is 
Len effect on IL2 a possible mechanism in MM cell killing beside the effect on 
IRF4 and MYC. 
 
Figure 2. Lenalidomide action on Cereblon. Reprinted from Oncoimmunology 
3(7): e941742.(119) Open Acces. 
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Other modern treatment modalities 
Proteasome inhibitors 
The first proteasome inhibitor (PI), Bortezomib (Bor) became available in the 
clinic in 2003 and 2004 after demonstration of efficacy in two phase II 
trials(120, 121). These studies were followed up by a randomized phase III 
study comparing Bor with high dose Dex, showing benefit in response rate and 
OS for Bor, despite substantial cross over from Dex to Bor(122, 123). Later on 
it was (as Thal) added to the old MP-regimen in a comparison MP to MP with 
added Bor (MPV) showing benefit for MPV with acceptable increase in side 
effects(124-126) and from that the drug was totally accepted as an efficient 
MM agent. 
Carfilzomib (Carf) is a newer PI, approved in US 2012 and in Europe in 2016. 
It has shown good effect as single drug(127), but has shown best effect in 
combination with Len and Dex in the ASPIRE study with an overall response 
rate (≥PR) of 87.1% in patients with relapsed MM(128). 
Ixazomib is an oral PI, but yet not approved in Europe. It has shown promising 
result, even in patients previously treated with Bor(129) and in combination 
with LenDex(130), showing slightly less overall response rate (78%) than the 
combination Carf with LenDex. 
 
Antibodies 
 A number of monoclonal antibodies against MM are under development and 
have been developed during the past years. The first one was daratumumab 
(Dara), an antibody against CD38, a transmembrane glycoprotein expressed on 
myeloid and lymphoid cells, but also on non-hematological tissues(131). It is 
especially expressed on MM cells(132). Dara has in a series of clinical studies 
shown severe toxic effects on MM cells and good clinical outcome on MM-
patients, both as single agent and in combinations with other drugs(133, 134). 
Elotuzumab, an antibody against signaling lymphocytic activating molecule 
family member 7 (SLAMF7), has no single drug effect on MM, but has shown 
promising results in combination with other anti MM agents. It has now singe 
agent effect on MM cells but in combination with other anti MM agents it has 
shown promising results. It works by binding both NK-cells and MM cells, 
triggering NK-cells and tagging the MM cells to make them more 
susceptible(135). It’s tested in clinical trials comparing Elotuzumab combined 
with LenDex to LenDex showing survival benefit for the combination(136) 
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Figure 3. Timeline of MM history 
 
Pharmacokinetics of Lenalidomide 
Len is mainly excreted by the kidneys and is to a very less extent a subject for 
metabolism. In vitro it is shown to have a half time due to hydrolyzes of 
approximately 8 hours(137), but as its halftime in plasma due to renal excretion 
is about 3 hours(138), the metabolism stands for a minimal part of the 
elimination. More than 80% of Len is found un-metabolized in the urine within 
24 hours after oral administration(139). In patients with renal impairment 
excretion is significantly prolonged. In patients with mild and severe renal 
impairment (CrCl <50 ml/min) less Len was excreted un-metabolized and half 
time was prolonged till 8-9 h(140). 
P-glycoprotein 
P-glycoprotein (P-gp) is a protein of the cell membrane and pumps foreign 
substances out of cells. It is distributed in intestinal epithelium, liver cells and in 
proximal tubules of the kidney. It is coded by the ABCB1-gene on chromosome 
7. It was initially discovered as it was interacting with several anti cancer 
drugs(141) and dysregulation of it is a well-characterized mechanism by which 
cancer cells in vitro avoid action of chemotherapeutic agents. Due to its 
distribution in both the intestinal epithelium and kidney tubules, it could both 
interact with Len uptake and excretion. An in vitro study showed that Len is a 
weak substrate for P-gp(142) and another small phase I clinical study, 
combining Len with the mechanistic target of rapamycin (mTOR)-inhibitor 
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CCI-779, also a substrate for P-gp, could show possible drug to drug interaction 
with elevated Len concentrations upon increased doses of CCI-779(143), this 
suggesting a clinically significant effect on uptake and excretion of Len from P-
gp inhibition. 
Single-Nucleotide Polymorphisms (SNPs) in the gene, ABCB1, have been 
associated with altered expression and phenotype in P-gp(144). In two previous 
studies(145, 146), colleagues have shown impact on survival in AML from 
variations in ABCB1 SNPs.  
 
 
. 
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2 AIMS 
 
As MM is an incurable disease and patients during their disease history 
receives several lines of treatment there is still a great need for new 
therapies; but there is also still a great need for getting better knowledge 
of the nature of the disease and to improve the knowledge of the existing 
treatment modalities to optimize the use of already existing drugs. 
All new drugs are today tested in randomized trials with patients selected 
due to several inclusion and exclusion criterias, thus making up a study 
population that always not correspond exactly to the normal, “real life” 
population of MM patients found outside the studies. A defined study 
population, followed from start of treatment and given a defined drug 
combination in defined doses and under a defined time is of course easier 
to study than patients treated in the clinic. But to know the outcome of 
different drugs and combinations in the clinical setting it is also of great 
value to do retrospective studies, indeed to prove that the results in 
clinical studies are accurate in the clinic. 
Aside the drugs we use there are several characteristics of MM that affect 
the prognosis of the disease. We know that the patients’ performance 
status, staging according to ISS, creatinin and calcium levels and 
chromosomal abnormalities affect the efficacy of a specific drug and 
survival of the patient. However, we do not today know much how to use 
these data when we choose which treatment to use in a specific patient. 
 
The specific aims of this thesis are: 
1. To identify the importance of existing drugs combinations, and to 
validate phase III studies with large population based cohorts. 
2. An attempt to identify/re-invistigate the impact of different 
chromosomal markers and attempt to identify new markers, gain 
1q21,  and their outcome for patients with MM. 
3. To investigate the importance of maintenance of Len in relapsed and 
refractory MM and evaluate whether there is an inevitable need for 
combining Rev with Dex upon achieving respons. 
4. To study clinical outcome in MM and compare it to different aspects 
of polymorphisms in DNA coding for a transport protein, P-
glycoprotein, regarding efficacy and side effects in patients treated 
with Len. 
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3  Materials and Methods 
Study population 
Paper I and II 
In paper 1 and 2 we retrospectively collected data from patient journals. 
In the first paper, data were collected from a database of all patients 
diagnosed with MM at 15 Swedish centers from January 2000 until June 
2011. Data including sex, age, type of MM, extent of bone disease, as 
well as laboratory measurements at diagnosis were collected. Serum M-
protein and Urine M-protein were collected at baseline and then followed 
until patients’ death, lost to follow up or until data cut-off. MM treatment 
data were collected with specific start- and stop-date for each drug or 
combination of drugs. Death dates, after the data collection, were obtained 
from the Swedish National Death Register. The study was focused on 
patients receiving MP or MPT in any of 1st, 2nd, 3rd or 4th line of treatment. 
From the data base cohort of 1843 patients, 1162 complied with the 
inclusion criteria for the study. 
In the second paper, we used retrospectively collected data from patient 
journals from centers in Sweden, Norway and Denmark from patients 
diagnosed in the years 2006 to 2011. The patient cohort from Sweden was 
the same as in the first study, but limited to the years from 2006. The 
study was based upon 930 MM-patients, but was limited to 347 patients 
with known FISH data of gain of 1q21. Data were collected on sex, age, 
type of MM, bone lesions, and laboratory measurements including M-
protein of serum and urine. As in the first paper response data and 
treatment data were followed up during the study to define responses and 
survival data. Death data outside the study were obtained from the central 
registers of the different countries. 
 
Paper III and IV 
Paper 3 and 4 are based upon two connected studies conducted in 
Sweden, Denmark and Norway. Patients were included from 9 Swedish, 2 
Danish and 1 Norwegian center. The first study was an observational, 
non-interventional phase IV study of Len naïve MM patients, refractory to 
or relapsed after their first line of treatment. Inclusion criteria included 
age ≥18 years and measurable disease defined as a serum M-protein of  
>0.5 g/dl or Bence Jones protein >20mg/24h. Patients with plasma cell 
leukemia, amyloidosis or non-hematological malignancies were excluded. 
133 patients were included and received standard dosing of lenalidomid 
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and dexamethasone - LenDex in 28 days cycles; Len 25 mg on days 1-21 
and Dex 40 mg on day 1, 8, 15 and 22. A maximum of 9 cycles were 
administered to each patient. After achieving at least partial remission 
(PR) and two additional treatment cycles patients were invited to join the 
second study. The second study was a prospective, randomized, open-
label phase II trial. 62 patients were randomized in a ratio of 1:1 to receive 
either single agent Len or to go on with combination treatment LenDex 
for up till 24 cycles or progression.  
 
Definition of Endpoints 
Treatment response was assessed according to IMWG criteria(55) with 
the exception of our own definition of nCR – (near Complete Remission). 
nCR was used as a complement to CR when the clinical praxis was to not 
perform a bone marrow sample in situations of immeasurable M-protein, 
but to distinguish the response from VGPR. 
In the papers we used the terms: 
TTNT – Time to next treatment, the time between treatment start in the 
current line of treatment and treatment start in the next line. 
PFS – Progression free survival or TTP – Time to progression, the time 
from start of a treatment line till progression or death. 
OS – Overall Survival, the time from start of a treatment line until death 
or last follow up. 
 
Statistical Methods 
Paper I 
To test differences between two independent groups we used Mann-
Whitney test. To evaluate differences in contingency tables Fisher´s exact 
test was used. Life time curves were calculated in accordance to Kaplan 
Meier and those were compared using log rank test. 
Paper II 
To test differences in patient characteristics and difference in response 
between subgroups, one way-ANOVA was used. To evaluate differences 
in contingency tables, Fisher´s exact test was used. To test for differences 
in OS and TTP between groups, log rank test was used. To evaluate 
predictive factors for survival, univariate and multivariate Cox 
proportional  hazard regressions were made. 
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Paper III 
Differences in patient characteristics were tested by ANOVA. For 
differences in contingency tables chi square test was used, or, for low 
frequencies, Fisher’s exact test. ANOVA with Kaplan Meier methods 
were used to compare survival data. 
Paper IV 
Survival data were calculated with log rank test for significance and 
assessed with Kaplan Meier graphs. Cox regression models were used for 
multivariate analyses to adjust for patient characteristics. Differences in 
AE between groups were compared with Chi2 test. The distribution of 
patient baseline characteristics were compared between genotype groups 
using Mann Whitney or Kruskal Wallis test for continuous variables, and 
Chi2 or Fisher´s exact test for categorical variables. 
In all studies a p-value of 0.05 was considered significant. 
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Response Serum M-
protein 
Urine M-protein Bone Marrow Free Light Chain 
Stringent 
Complete 
Response (sCR) 
Undetectable by 
immunofixation 
Undetectable by 
immunofixation 
Absence of 
clonal cells 
Normal free 
light chain ratio 
Complete 
Response (CR) 
Undetectable by 
immunofixation 
Undetectable by 
immunofixation 
≤5% plasma 
cells 
 
Very good 
Complete 
Response 
(VGPR) 
≥90% reduction <100 mg /24h   
Partial Response 
(PR) 
≥50% reduction ≥90% reduction 
and <200 mg 
/24h 
  
No Response 
(NR) 
≤50% reduction    
Progressive 
Disease (PD) 
25% increase, 
≥0,5 g/dl 
25% increase, or 
increase of ≥200 
mg/24h 
  
Table 2 IMWG response criteria 
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  4  Results and Discussion 
The recent two decades have presented an astonishing development in 
diagnosing and treating MM. Stem cell transplant has provided great 
benefit for younger patients and the evolvement of the “novel” drugs has 
since Barlogie’s first attempt with thalidomide revolutionized treatment in 
both young and elderly patients. Diagnostics has also improved. New 
methods in characterizing malignant diseases from conventional 
cytogenetics via FISH to molecular genetics as Next Generation of 
Sequencing gives us enormous potential in classification, risk estimation 
and determination of which drug or combination of drug and in which 
order to give to each patient. We have in four papers looked upon some 
aspects of this. 
Pros and cons Retrospective studies vs. Prospective ones 
We have in two retrospective studies analyzed outcome in “real life 
patients” in a way to try to translate results in multiple prospective studies 
to the clinical praxis. It is well known that the prospective clinical trials 
provide us with controlled results with a certain level of statistical 
significance. From the statistical significance of the studies we also could 
draw conclusions about similar patients to them participating in the 
certain study. However, the study populations in clinical studies are 
highly selective. Certain exclusion and inclusion criteria provide studies 
with a manageable group of study objects, often lacking patients from a 
certain age, with certain performance status etc. Furthermore, specific 
studies are often designed to answer specific questions; e.g. a certain drug 
in a certain line of therapy and takes not much account of what happened 
before the study and what happened after. Here, I think, wide 
retrospective studies have a role.  
In a retrospective population based study you have all patients and not a 
selected group that you in some way have to “interpret” when to draw 
conclusions to your own “real life patients”. You have also information 
from the beginning to the very end. In clinical studies you often do not 
have the time to follow up patients for many years, results must be 
published, and survival endpoints are presented as PFS and TTP instead 
of OS. 
The great problem with the retrospective setting is that there is no control 
of the groups that are studied. If the study is to study differences in 
outcome between two groups of patients that were given different 
medication it is likely that patient characteristics as age, performance 
status, lab data influences the clinician’s choice and there makes the 
studied groups different from the beginning, interfering with the results. 
There are statistical methods, at least partially, to overcome this problem, 
but the problem still is there, making data from population based studies 
graded lower when it comes to evidence grading. 
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Thalidomide in clinical practice 
After the introduction of thalidomide in 1999(93), six prospective 
randomized studies were performed comparing the benefits of the 
combination of melphalan and prednisone (MP) with melphalan 
prednisone and thalidomide (MPT)(102, 103, 147-150) showing better 
outcome for the latter. A meta analysis of these studies showed increased 
progression free survival and overall survival of 6 months(151).  
From our retrospective register where we collected data from all 1843 
patients diagnosed with MM from January 2000 to June 2011 at 15 
different Swedish hospitals, we sorted out all patients treated with MP or 
MPT, providing us with a complete cohort of all patients from a defined 
population given those drug combinations. From the study group, we 
selected all patients given MP or MPT in first, second, third and fourth 
line of therapy, a total of 888 patients. We could show differences in 
overall survival favoring MPT in all studied lines of therapy, but the 
results were not significant in line three and four, maybe due to too small 
groups, but also maybe due to lack benefit from intense treatment in 
heavy pretreated patients. 
The results in first line were a bit surprising; as mentioned above, meta 
analysis of previous randomized studies showed a median OS-benefit of 6 
months favoring MPT and we could show a significant difference of 2 
years (2,2 vs. 4.2 years for MP vs. MPT respectively)(152). Of course 
there has to have been problems with selection basis; as a physician you 
probably do not choose to add a likely more poisonous drug to a fragile 
and elderly patient, but still, after adjusting for differences in prognostic 
factors as hemoglobin, creatinine and albumin levels the results were still 
significant and the difference in age between the group was minor 
(median age 77 vs. 75 years). The question was also raised whether there 
were differences in supportive care due to that MP and MPT were given 
in different time periods since we started collection of patient data before 
thalidomide got its permission and that it took a while until it was fully 
introduced in the clinical practice. To solve that issue we also compared 
patient treated with MP in the same time period as patients treated with 
MPT and the differences in survival were still significant. 
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A 
 
B 
Figure 3. Overall survival for patients treated with MP compared to MPT. 
1st line A, 2nd line B 
 
 Gain of 1q21 
In paper II(67) another retrospectively collected patient cohort was 
analyzed. In this study patients came from three Nordic countries - 
Sweden, Denmark and Norway. The Swedish patients were partly the 
same as in paper II, but limited to a shorter time period, as mentioned 
above. We knew that gain 1q21 is one of the most common aberrations in 
MM and that it is linked to an overexpression in Cyclin-dependent kinases 
regulatory subunit 1 (CKS1B) which is associated to a worse prognosis in 
MM(153). The question here was whether we could show, in our 
retrospectively studied patients, a difference in outcome based on FISH 
data on the chromosomal abnormality of gain of1q21 and if it was 
possible to overcome this assumed worse prognosis by treating with novel 
agents vs. conventional cytostatics. We had data from 930 patients, but 
had to limit the study to 347 patients with known FISH data on gain of 
1q21. 
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The cohort was divided into 3 groups: gain of 1q21 (n=119), other 
chromosomal abnormalities (OA) (defined as del(13q), del(17p), t(4;14), 
and/or t(14;16)) (n=105) and a group with no abnormalities or other than 
the ones listed above (NO) (n=123). 
Results on survival between the groups treated with conventional 
cytostatics were in line with our assumption. OS was better in the NO 
group compared to the two groups with chromosomal abnormality. No 
difference could be seen between the gain 1q21 and the OA groups. We 
could show, in line with previous randomized studies(69, 72), that treating 
with novel agents (Thal, Bor and Len) could overcome the negative 
impact of chromosomal aberrations. However, in our material, the 
negative impact of gain 1q21 still existed, despite use of novel agents. 
 
 
Figure 4. OS comparing patients with gain 1q21, other abnormalities 
(del(13q), del(17p), t(4;14) or t(14;16) (OA) and no abnormalities (NO) 
treated with A; conventional cytostatic agents B; Thal, Bort or Len 
 
Need for different kind of studies? 
Thus, in paper I and II, we could in our retrospective setting show up with 
similar results as in previously performed clinical studies and in some 
way prove that their results are possible to transform into the clinical 
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praxis. As discussed before, clinical trials have their disadvantages (and 
so do retrospective studies!), and we find it important to assess the results 
from studies and see if they still are valid when it comes to clinic.  
From our data in paper II, we could also show new results on gain 1q21. 
No clinical study has put up the question whether negative impact on 
survival from gain 1q21 could be overcome by use of PIs or IMiDs. This 
question will remain unanswered without a prospective clinical trial; 
however, well-designed retrospective studies can hint the answer. 
 
Lenalidomide 
In paper III and IV we studied lenalidomide as second line treatment in 
relapsed or refractory MM. The patient groups are discussed above. At the 
time of the study the indication for use of lenalidomide was in second or 
later lines of therapy base upon two studies by Dimopoulos and by 
Weber(108, 109). The study design was to treat a patient group with the 
standard treatment of lenalidomide and dexamethasone (LenDex), and 
upon response, to randomize into two groups – one with continuous 
standard treatment of, LenDex and the other with Len as single drug.  
Prolonged treating with corticosteroids has lots of side effects and to 
exclude it from MM could possibly give benefit to patients. In vitro 
studies showed that Thal and other IMiDs could enhance interleukin 2 
(IL2) and interferon gamma (IFN-gamma) production and enhance NK-
cell mediated MM cell killing(154) and that this effect from Len was 
depleted by adding corticosteroids(118). Thus we designed the study to 
first get a response from LenDex and then to see whether it was possible 
to withdraw Dex. 
The response rate (PR or better) in our study was better than in the studies 
by Dimopoulos and Weber (79% vs. 60% and 61% respectively), and so 
was TTP (19 months vs. 11.3 and 11.1 months), but our study was 
restricted to patients in second line of treatment and theirs to second or 
later lines. 
We could see no difference in OS between the groups in the observational 
part of the study (Len vs. LenDex). There was a trend towards better TTP, 
favoring LenDex, but the result was not significant. We could not, 
however, see any phenotype differences among circulating lymphocytes 
including NK-cells. The conclusion would be that LenDex is a safe 
treatment regimen and that prolonged treatment with Len of LenDex after 
achieving at least a PR provides sustained and clinically relevant 
responses.  
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Figure 5. PFS in phase II study comparing Len vs. LenDex 
 
 
Figure 6. OS in phase II study comparing Len vs. LenDex 
The pharmacokinetic studies of paper IV could show no significant effect 
of any ABCB1 variant on Len treatment response, OS, TTP or risk of 
hematological AE. We could see a trend to that the variant 1199G>A 
could show a little longer TTP. The effect of P-gp on the excretion and 
uptake of Len is probably minor and our study is small. To answer the 
question whether there is an actual effect or not, we will have to perform a 
bigger study and also include measurement of Len concentration in serum 
and maybe also urine to link the knowledge on genotype with clinical 
outcome in a more certain way. 
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Figure 7. TTP in relation to 1199G>A genotype. 
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5 Future Perspectives 
 
Although there has been several progress in understanding biology of 
MM, and its implication both to the nature of the disease, and to improve 
treatment modalities, there is still much to do. MM is still classified as an 
incurable disease, and most patients diagnosed with MM, except the very 
elderly, will die from MM. 
Today, we choose treatments from factors relating to the patient, e.g. 
performance status, age etc. We don’t consider disease specific factors, as 
chromosomal abnormalities and different gene expression, in some 
significant extent, when to choose treatment modalities. 
It would be great to improve the knowledge on chromosomal 
abnormalities and see if MM with certain modalities were more 
susceptible to certain treatments. We have seen, when we changed from 
therapy with classical cytostatics into what was called “novel agents”, that 
certain “high risk” abnormalities could be overcome by treating with 
Thal, Bor of Len. Now, it would be interesting if there were differences 
between today’s treatment modalities, when it comes to different 
prognostic markers. 
Further studies on pharmacogenetics, a still not much explored research 
field when it comes to MM, would also possibly improve treatment of 
MM. It would be of great interest to set up a study to compare serum 
levels of certain drugs, to compare it to genetic markers on uptake and 
excretion, and to clinical outcome. 
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